Fig. 7

tPA stimulates MOG_35–55-dependent APC maturation and T cell proliferation via its EGF-like domain. Splenocytes extracted from EAE mice at the peak of the clinical course were treated in the indicated conditions. a, b MHC-II MFI in a CD11c⁺MHC-II⁺-DCs and b F4/80⁺ MHC-II⁺-MΦs exposed to 2 μg/mL of tPA or 2 μg/mL of tPA-GGACK. c, d Expression of MHC-II MFI in c CD11c⁺MHC-II⁺-DCs and d F4/80⁺ MHC-II⁺-MΦs after combined treatment with 2 μg/mL of tPA and 5-μM EGFR inhibitor AG1478. e, f Cell proliferation index of e CD4⁺ and f CD8⁺ T cells after combined treatment with 5 μg/mL MOG_35–55, 2 μg/mL of tPA and 5-μM EGFR inhibitor AG1478. N = 6–7 and ^*P < 0.05, ^**P < 0.01, ^***P < 0.001 vs control; ^#P < 0.05, ^###P < 0.001 vs tPA. g, h Cell proliferation index of sorted g CD4⁺ and h CD8⁺ T cells in co-culture with MOG-stimulated CD3 T cell-depleted splenocytes with/without 2 μg/mL of tPA during 24 or 96 h (N = 6–7 for a–f, N = 3 for g and h, and ^*P < 0.05, ^**P < 0.01, ^***P < 0.001 vs baseline; ^#P < 0.05, ^###P < 0.001 vs tPA)